Table S3. **Characterization of disease symptomatology in GABAAR encephalitis mouse model.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Group | Animal number | Symptoms compatible with impaired GABAergic inhibition | Symptom onset after pump implantation [day] | Disease course |
| #113-115 IgG high dose | 1 | Occasional myoclonus/twitching, stereotypic movements (circling) | 4 | Euthanasia due to seizure activity and poor physical condition (day 10) |
| 2 | Occasional myoclonus/twitching | 3 | Unexpected death (day 3) |
| 3 | none | - | Survival until end of experiment |
| 4 | Periodic myoclonus/twitching, myoclonus, stereotypic movements (circling); increased muscle tone | 3 | Euthanasia due to seizure activity and poor physical condition (day 3) |
| 5 | Occasional myoclonus/twitching | 4 | Unexpected death (day 7) |
| 6 | Occasional myoclonus/twitching | 8 | Unexpected death (day 8) |
| 7 | Occasional myoclonus/twitching | 13 | Unexpected death (day 13) |
| #113-115 Fab high dose | 1 | Myoclonus/twitching, gait ataxia, hunched posture, increased muscle tone, stereotypic movements (circling) | 3 | Euthanasia due to seizure activity and poor physical condition (day 4) |
| 2 | Gait ataxia | 9 | Euthanasia due to seizure activity and poor physical condition (day 10) |
| 3 | Hunched posture, gait ataxia, myoclonus/twitching | 3 | Euthanasia due to seizure activity and poor physical condition (day 3) |
| 4 | Periodic myoclonus/twitching, hunched posture, increased muscle tone | 4 | Euthanasia due to seizure activity and poor physical condition (day 4) |
| 5 | Occasional myoclonus/twitching | 9 | Unexpected death (day 9) |
| #113-115 IgG low dose | 1 | none | - | Survival until end of experiment |
| 2 | Gait ataxia, occasional myoclonus/twitching, stereotypic movements (circling), increased muscle tone | 6 | Unexpected death (day 10) |
| 3 | stereotypic movements (circling), gait ataxia | 10 | Survival until end of experiment |
| 4 | none | - | Survival until end of experiment |
| 5 | none | - | Survival until end of experiment |
| 6 | none | - | Survival until end of experiment |
| control IgG high dose | 1 | none | - | Survival until end of experiment |
| 2 | none | - | Survival until end of experiment |
| 3 | none | - | Survival until end of experiment |
| 4 | none | - | Survival until end of experiment |
| 5 | none | - | Survival until end of experiment |

An overview of symptoms is shown observed in C57BL/6 mice that received cerebroventricular infusion of the human GABAAR mAb #113-115 or control mAb #mGO53 over 14 d. The animals continuously received 1.5 µg of IgG or equimolar Fab per hour in the high-dose groups or 0.3 µg of IgG per hour in the low-dose group. The mice were sacrificed at predefined humane endpoints approved by local authorities as indicated or after the end of experiment at day 15 after pump implantation.